Clinical Trial

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

Recruiting
View on ClinicalTrials.gov →
Summary
Febrile neutropenia (FN) is a common oncologic emergency in patients with hematologic malignancies, associated with high morbidity and mortality. Early identification of patients at higher risk of complications such as sepsis or septic shock is critical to optimize antimicrobial management. This study aims to characterize the human and microbial plasma proteome using high-resolution mass spectrometry to identify biomarker combinations ("combitypes") capable of predicting complications in oncohematologic patients with FN. A cohort of 350 adult patients with high-risk FN and initially uncomplicated clinical presentation will be enrolled across three tertiary hospitals. Plasma samples will be collected at fever onset (before antibiotic initiation) and after 48 hours. Proteomic data will be integrated with clinical information using multivariate and machine learning models to develop a predictive model for complications.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-16
Trial Details
NCT Number NCT07277387
Lead Sponsor Instituto de Investigación Biomédica de Salamanca
Conditions Febrile Neutropenia
Enrollment 350 participants
Start Date 2026-06-09
Primary Completion 2028-12 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-15